Guardian Capital (Canada)’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$33.6M Buy
177,185
+6,933
+4% +$1.3M 0.82% 36
2026
Q1
$33.6M Buy
170,252
+137,515
+420% +$26.5M 0.89% 35
2025
Q4
$6.02M Sell
32,737
-8,800
-21% -$1.54M 0.18% 76
2025
Q3
$6.37M Buy
41,537
+9,824
+31% +$1.49M 0.21% 76
2025
Q2
$4.43M Buy
31,713
+2,748
+9% +$385K 0.16% 82
2025
Q1
$4.26M Sell
28,965
-511
-2% -$73.9K 0.17% 83
2024
Q4
$3.86M Buy
29,476
+2,249
+8% +$315K 0.14% 85
2024
Q3
$4.24M Sell
27,227
-763
-3% -$123K 0.16% 79
2024
Q2
$4.37M Buy
27,990
+1,853
+7% +$279K 0.16% 77
2024
Q1
$3.54M Buy
26,137
+2,492
+11% +$330K 0.12% 82
2023
Q4
$3.18M Sell
23,645
-2,415
-9% -$314K 0.11% 83
2023
Q3
$3.53M Sell
26,060
-867
-3% -$118K 0.13% 84
2023
Q2
$3.85M Sell
26,927
-628
-2% -$92.4K 0.12% 82
2023
Q1
$3.83M Sell
27,555
-1,266
-4% -$170K 0.12% 86
2022
Q4
$3.91M Sell
28,821
-664
-2% -$83.3K 0.13% 86
2022
Q3
$3.23M Buy
29,485
+1,677
+6% +$213K 0.11% 88
2022
Q2
$3.67M Buy
27,808
+9,737
+54% +$1.28M 0.11% 91
2022
Q1
$2.4M Buy
18,071
+146
+0.8% +$17.5K 0.05% 103
2021
Q4
$2.09M Sell
17,925
-1,775
-9% -$209K 0.04% 111
2021
Q3
$2.37M Sell
19,700
-411
-2% -$47.8K 0.05% 106
2021
Q2
$2.41M Buy
20,111
+169
+0.8% +$18.5K 0.05% 106
2021
Q1
$1.98M Sell
19,942
-8,376
-30% -$842K 0.03% 112
2020
Q4
$2.83M Sell
28,318
-35
-0.1% -$3.71K 0.07% 87
2020
Q3
$3.11M Buy
28,353
+66
+0.2% +$7.34K 0.08% 82
2020
Q2
$2.99M Sell
28,287
-170
-0.6% -$17.6K 0.08% 77
2020
Q1
$2.54M Buy
28,457
+11,069
+64% +$1.04M 0.08% 74
2019
Q4
$1.73M Sell
17,388
-27,010
-61% -$2.54M 0.04% 86
2019
Q3
$3.96M Buy
44,398
+9,013
+25% +$781K 0.08% 77
2019
Q2
$2.92M Buy
35,385
+1,969
+6% +$154K 0.06% 85
2019
Q1
$2.7M Sell
33,416
-30,576
-48% -$2.41M 0.05% 88
2018
Q4
$4.86M Sell
63,992
-6,741
-10% -$526K 0.1% 85
2018
Q3
$5.6M Sell
70,733
-1,083
-2% -$81.9K 0.09% 91
2018
Q2
$5.04M Sell
71,816
-6,528
-8% -$470K 0.09% 98
2018
Q1
$5.48M Sell
78,344
-1,284
-2% -$88.9K 0.09% 96
2017
Q4
$5.53M Sell
79,628
-1,761
-2% -$119K 0.08% 97
2017
Q3
$5.51M Sell
81,389
-1,600
-2% -$101K 0.08% 110
2017
Q2
$5.66M Sell
82,989
-1,630
-2% -$106K 0.09% 112
2017
Q1
$5.27M Sell
84,619
-4,270
-5% -$249K 0.08% 117
2016
Q4
$4.86M Sell
88,889
-6,242
-7% -$354K 0.07% 112
2016
Q3
$6.25M Sell
95,131
-421
-0.4% -$27.5K 0.1% 102
2016
Q2
$5.77M Buy
95,552
+56,936
+147% +$3.31M 0.09% 101
2016
Q1
$2.17M Sell
38,616
-64,627
-63% -$3.88M 0.04% 118
2015
Q4
$7.01M Sell
103,243
-72
-0.1% -$4.72K 0.13% 87
2015
Q3
$6.58M Buy
103,315
+179
+0.2% +$11.8K 0.12% 84
2015
Q2
$6.57M Buy
103,136
+27,930
+37% +$1.91M 0.11% 89
2015
Q1
$5.15M Sell
75,206
-2,892
-4% -$201K 0.09% 99
2014
Q4
$5.5M Sell
78,098
-1,900
-2% -$136K 0.09% 88
2014
Q3
$5.71M Buy
79,998
+2,573
+3% +$188K 0.09% 93
2014
Q2
$5.75M Sell
77,425
-10,928
-12% -$790K 0.08% 95
2014
Q1
$5.73M Buy
88,353
+2,261
+3% +$146K 0.09% 92
2013
Q4
$5.11M Buy
86,092
+37,260
+76% +$2.02M 0.08% 91
2013
Q3
$2.54M Buy
48,832
+1,867
+4% +$93.8K 0.04% 104
2013
Q2
$2.22M Buy
+46,965
New +$2.39M 0.04% 105

Other funds holding AZN

Guardian Capital (Canada)'s AZN Position: Q2 2026 in Review

Guardian Capital (Canada) increased its AstraZeneca (AZN) stake by 4.1% in Q2 2026, buying an estimated $1.3M and bringing the position to 177,185 shares worth $33.6M. The position accounts for 0.82% of the portfolio, ranked #36.

Guardian Capital (Canada) first reported a position in AZN in Q2 2013 and has held it in 53 quarters since. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Guardian Capital (Canada) held 177,185 shares of AstraZeneca worth $33.6M as of Q2 2026.
  • Guardian Capital (Canada) bought 6,933 AstraZeneca shares in Q2 2026, an estimated $1.3M.
  • AstraZeneca made up 0.82% of Guardian Capital (Canada)'s portfolio in Q2 2026, its #36 holding.
  • Guardian Capital (Canada) first reported a position in AstraZeneca in Q2 2013 and has held it in 53 quarters since.
  • 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Guardian Capital (Canada)'s 13F filing for Q2 2026, filed 14 Aug 2026.